A search was made for an ideal drug marker to use in a long-term clinical trial. Sodium fluorescein (4 mg.) was shown to impart urine fluorescence which could be easily and specifically detected. The incorporation of this substance as a marker in the chlorpropamide versus placebo trial for sub-clinical diabetes mellitus is described.
Get full access to this article
View all access options for this article.
References
1.
JonesI. H. (1967). Riboflavine as an indicator of drug taking behaviour. Medical Journal of Australia, 1, 202
2.
McPhailA. I. (1962). Personal communication.
3.
SilbersteinR. M.BlackmanS. (1966). A method to evaluate whether patients take prescribed medication. Clinical Paediatrics, 5, 239
4.
SwintoskyJ. V. (1962). Riboflavine marker in drug products. Journal of Pharmacological Science, 51, 1015
